Skip to main content
. Author manuscript; available in PMC: 2008 Nov 7.
Published in final edited form as: Vaccine. 2007 Sep 4;25(45):7824–7831. doi: 10.1016/j.vaccine.2007.08.036

Figure 4. In vivo tumor treatment experiment in challenged mice vaccinated with combinations of the SCT and Bcl-xL DNA vaccines.

Figure 4

Figure 4

C57BL/6 mice were intravenously challenged with 1×104 TC-1/Luciferase cells/mouse by tail-vein injection. Three days after tumor challenge, mice were treated with combinations of SCT-E6 or OVA DNA with Bcl-xL or mtBcl-xL DNA vaccines three times at 3-day intervals. Mice were imaged using the Xenogen IVIS Imaging System Series 200. Bioluminescence signals were acquired for one minute. (A) Images of representative tumor-challenged mice vaccinated with combinations of SCT and Bcl-xL DNA vaccines from day 36 after tumor challenge. (B) Bar graphs depicting the luminescent intensities of lung tumors in tumor-challenged mice on day 36 after tumor challenge (*p<0.05). (C) Line graph depicting the luminescent intensities of lung tumors in tumor-challenged mice, which represent tumor volume, over time.